Odyssey Health, Inc. remains in an early-stage development phase with no commercial products currently generating revenue. The June 2026 quarter disclosed an extension of a key convertible promissory note’s maturity to September 2026, reflecting ongoing financing management amid constrained liquidity. The company continues advancing its product pipeline, emphasizing the CardioMap heart monitoring device and the Save-A-Life choking rescue device, both awaiting regulatory approvals. Odyssey Health's business model relies heavily on licensing partnerships and third-party commercialization efforts, but significant risks persist around regulatory clearances, capital availability, and clinical validation milestones.